TRXBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
TRex Bio, Inc.
$14.80+0.79 (+5.64%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns TRex Bio's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ELI LILLY & Co | 5,480,872 | 19.90% | 13D (active) | Oct 13, 2026 |
| Pfizer Inc. (13-5315170) | 1,965,066 | 7.20% | 13G (passive) | Oct 8, 2026 |
| SV Biotech Crossover Opportunities Fund LP | 1,920,667 | 7.00% | 13D (active) | Oct 8, 2026 |
| Johnson & Johnson Innovation - JJDC, Inc. | 1,475,302 | 5.30% | 13G (passive) | Oct 13, 2026 |